What is Fresenius Med Cr's earnings per share (EPS)?

Fresenius Med Cr (FMCQF) reported diluted earnings per share of $4.06 for fiscal year 2016. This represents a 17.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Fresenius Med Cr Financials

FMCQF

Source SEC Filings (10-K/10-Q) Data as of Dec 31, 2016 Currency USD FYE December

This page shows Fresenius Med Cr (FMCQF) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI FMCQF FY2016 2026-04-22

Cash-backed earnings and gradual deleveraging define a business that still must reinvest heavily to keep cash free.

From FY2015 to FY2016, operating margin expansion from 13.9% to 14.7% happened alongside balance-sheet repair: long-term debt fell from $7.9B to $7.2B, while operating cash flow remained above net income at $2.1B versus $1.2B. That combination suggests the improvement was not just accounting profit; the business was turning earnings into cash and using that cash to reduce leverage at the same time.

Free cash flow durability is decent but not effortless: FY2016 free cash flow of $1.1B came after capital spending of $1.0B, so the company still produced surplus cash only after a substantial reinvestment burden. With free cash flow margin at 6.2% versus operating margin at 14.7%, a meaningful share of operating profit is consumed before it becomes truly flexible cash.

The balance sheet is becoming less levered, but it remains goodwill-heavy: goodwill of $13.7B is larger than total equity of $10.8B. That means book value depends heavily on acquired intangible balances, so retained earnings and debt reduction are doing more of the financial strengthening than the cash balance alone.

Financial Health Signals

Financial health score pending refresh

We are recalculating Fresenius Med Cr's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Altman Z-Score Grey Zone

2.05

Fresenius Med Cr scores 2.05, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Strong

7/9

Fresenius Med Cr passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

1.72x

For every $1 of reported earnings, Fresenius Med Cr generates $1.72 in operating cash flow ($2.1B OCF vs $1.2B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

5.8x

Fresenius Med Cr earns $5.8 in operating income for every $1 of interest expense ($2.6B vs $452.2M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$17.9B

YoY+240.2%

5Y CAGR+9.8%

Fresenius Med Cr generated $17.9B in revenue in fiscal year 2016. This represents an increase of 240.2% from the prior year.

EBITDA

$3.4B

YoY+15.6%

5Y CAGR+9.1%

Fresenius Med Cr's EBITDA was $3.4B in fiscal year 2016, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 15.6% from the prior year.

Net Income

$1.2B

YoY+18.9%

5Y CAGR+6.9%

Fresenius Med Cr reported $1.2B in net income in fiscal year 2016. This represents an increase of 18.9% from the prior year.

EPS (Diluted)

$4.06

YoY+17.7%

5Y CAGR+6.3%

Fresenius Med Cr earned $4.06 per diluted share (EPS) in fiscal year 2016. This represents an increase of 17.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$1.1B

YoY+19.4%

5Y CAGR+7.7%

Fresenius Med Cr generated $1.1B in free cash flow in fiscal year 2016, representing cash available after capex. This represents an increase of 19.4% from the prior year.

Cash & Debt

$747.2M

YoY+17.9%

5Y CAGR+19.9%

Fresenius Med Cr held $747.2M in cash against $7.2B in long-term debt as of fiscal year 2016.

Dividends Per Share

$0.80

YoY+3.9%

Fresenius Med Cr paid $0.80 per share in dividends in fiscal year 2016. This represents an increase of 3.9% from the prior year.

Shares Outstanding

306M

YoY+0.9%

5Y CAGR+0.7%

Fresenius Med Cr had 306M shares outstanding in fiscal year 2016. This represents an increase of 0.9% from the prior year.

Margins & Returns

Gross Margin

32.3%

YoY+138.1pp

5Y CAGR-1.8pp

Fresenius Med Cr's gross margin was 32.3% in fiscal year 2016, indicating the percentage of revenue retained after direct costs. This is up 138.1 percentage points from the prior year.

Operating Margin

14.7%

YoY-28.1pp

5Y CAGR-0.9pp

Fresenius Med Cr's operating margin was 14.7% in fiscal year 2016, reflecting core business profitability. This is down 28.1 percentage points from the prior year.

Net Margin

6.9%

YoY-12.9pp

5Y CAGR-1.0pp

Fresenius Med Cr's net profit margin was 6.9% in fiscal year 2016, showing the share of revenue converted to profit. This is down 12.9 percentage points from the prior year.

Return on Equity

11.5%

YoY+0.4pp

5Y CAGR-1.9pp

Fresenius Med Cr's ROE was 11.5% in fiscal year 2016, measuring profit generated per dollar of shareholder equity. This is up 0.4 percentage points from the prior year.

Capital Allocation

R&D Spending

$162.4M

YoY+33.0%

5Y CAGR+11.6%

Fresenius Med Cr invested $162.4M in research and development in fiscal year 2016. This represents an increase of 33.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$1.0B

YoY+10.6%

5Y CAGR+12.4%

Fresenius Med Cr invested $1.0B in capex in fiscal year 2016, funding long-term assets and infrastructure. This represents an increase of 10.6% from the prior year.

FMCQF Income Statement

Metric	FY16	FY14	FY13	FY11	FY10	FY09
Revenue	$17.9B+240.2%	$5.3B+5.9%	$5.0B-60.5%	$12.6B+6.1%	$11.8B+5.3%	$11.2B
Cost of Revenue	$12.1B+12.0%	$10.8B+9.8%	$9.9B+17.3%	$8.4B+5.1%	$8.0B+8.0%	$7.4B
Gross Profit	$5.8B+203.8%	-$5.6B-13.7%	-$4.9B-218.0%	$4.2B+8.3%	$3.8B+0.1%	$3.8B
R&D Expenses	$162.4M+33.0%	$122.1M-2.9%	$125.8M+13.5%	$110.8M+14.8%	$96.5M+2.9%	$93.8M
SG&A Expenses	$3.0B+15.2%	$2.6B+11.0%	$2.4B+19.0%	$2.0B+9.8%	$1.8B-8.2%	$2.0B
Operating Income	$2.6B+17.0%	$2.3B-0.1%	$2.3B+8.7%	$2.1B+7.9%	$1.9B+9.6%	$1.8B
Interest Expense	$452.2M-8.7%	$495.4M+10.7%	$447.5M+25.6%	$356.4M+16.7%	$305.5M-4.9%	$321.4M
Income Tax	$683.1M+17.1%	$583.6M-1.4%	$592.0M-1.5%	$601.1M+3.9%	$578.3M+17.9%	$490.4M
Net Income	$1.2B+18.9%	$1.0B-5.8%	$1.1B+3.6%	$1.1B+9.5%	$978.5M+9.8%	$891.1M
EPS (Diluted)	$4.06+17.7%	$3.45-5.5%	$3.65+4.0%	$3.51+8.3%	$3.24+8.4%	$2.99

Metric	Q4'16	Q3'16	Q2'16	Q1'16	Q4'15	Q3'15	Q2'15	Q1'15
Revenue	$4.7B+1.9%	$4.6B+4.0%	$4.4B+5.1%	$4.2B-49.4%	$8.3B+96.2%	$4.2B+0.8%	$4.2B+10.6%	$3.8B
Cost of Revenue	$3.1B-1.0%	$3.1B+3.5%	$3.0B+4.7%	$2.9B+0.3%	$2.9B+1.0%	$2.8B-1.8%	$2.9B-99.9%	$2.8T
Gross Profit	$1.6B+8.2%	$1.5B+5.2%	$1.4B+6.1%	$1.3B-75.7%	$5.4B+292.6%	$1.4B+6.5%	$1.3B+100.0%	-$2.8T
R&D Expenses	$42.2M-3.8%	$43.9M+13.2%	$38.8M+3.4%	$37.5M-6.2%	$39.9M+14.3%	$34.9M+1.3%	$34.5M-99.9%	$30.9B
SG&A Expenses	$767.2M-2.5%	$786.8M+7.5%	$732.1M-3.5%	$758.5M-2.2%	$775.7M+4.5%	$742.3M+2.7%	$722.6M-99.9%	$654.9B
Operating Income	$786.2M+17.4%	$669.9M+4.5%	$641.1M+18.7%	$540.3M-18.4%	$661.8M+7.9%	$613.5M+12.2%	$547.0M-99.9%	$504.4B
Interest Expense	$106.0M-3.5%	$109.9M-8.4%	$119.9M+3.0%	$116.4M-6.8%	$124.9M+17.9%	$105.9M-8.0%	$115.1M-99.9%	$162.0B
Income Tax	$212.2M+29.2%	$164.2M-2.5%	$168.4M+21.8%	$138.3M-23.4%	$180.5M+7.1%	$168.4M+24.4%	$135.4M-99.9%	$137.9B
Net Income	$388.1M+16.5%	$333.2M+13.3%	$293.9M+28.9%	$228.0M-28.0%	$316.8M+20.8%	$262.3M+9.0%	$240.8M-99.9%	$209.5B
EPS (Diluted)	N/A	N/A	N/A	$0.75	N/A	$0.86	N/A	$0.69

FMCQF Balance Sheet

Metric	FY16	FY14	FY13	FY11	FY10	FY09
Total Assets	$26.9B+6.1%	$25.4B+9.8%	$23.1B+18.4%	$19.5B+14.3%	$17.1B+8.0%	$15.8B
Current Assets	$7.3B+8.9%	$6.7B+6.9%	$6.3B+10.4%	$5.7B+10.5%	$5.2B+9.0%	$4.7B
Cash & Equivalents	$747.2M+17.9%	$633.9M-7.2%	$682.8M+49.3%	$457.3M-12.5%	$522.9M+73.6%	$301.2M
Inventory	$1.4B+26.4%	$1.1B+1.7%	$1.1B+13.4%	$967.5M+19.6%	$809.1M-1.5%	$821.7M
Accounts Receivable	$3.5B+10.0%	$3.2B+5.5%	$3.0B+8.5%	$2.8B+8.7%	$2.6B+12.6%	$2.3B
Goodwill	$13.7B+4.5%	$13.1B+12.2%	$11.7B+26.9%	$9.2B+5643.5%	$159.9M-97.9%	$7.5B
Total Liabilities	$14.2B-2.0%	$14.5B+11.9%	$13.0B+17.4%	$11.1B+19.1%	$9.3B+5.7%	$8.8B
Current Liabilities	$5.0B+44.9%	$3.5B-2.2%	$3.6B-16.6%	$4.3B+12.5%	$3.8B+45.2%	$2.6B
Long-Term Debt	$7.2B-20.1%	$9.0B+16.4%	$7.7B+41.0%	$5.5B+27.5%	$4.3B-2.7%	$4.4B
Total Equity	$10.8B+14.5%	$9.4B+2.3%	$9.2B+16.9%	$7.9B+7.1%	$7.4B+10.5%	$6.7B
Retained Earnings	$8.8B+24.4%	$7.1B+11.4%	$6.4B+37.2%	$4.6B+20.5%	$3.9B+24.0%	$3.1B

Metric	Q4'16	Q3'16	Q2'16	Q1'16	Q4'15	Q3'15	Q2'15	Q1'15
Total Assets	$26.9B+1.0%	$26.7B+0.4%	$26.6B+1.9%	$26.1B+2.8%	$25.4B-0.2%	$25.4B0.0%	$25.4B-99.9%	$25.1T
Current Assets	$7.3B+1.3%	$7.2B-0.8%	$7.3B+1.8%	$7.1B+5.6%	$6.8B+0.1%	$6.8B+0.9%	$6.7B-99.9%	$6.6T
Cash & Equivalents	$747.2M+18.6%	$629.8M-12.9%	$722.7M+39.6%	$517.8M-5.8%	$549.5M-11.6%	$621.4M+6.7%	$582.2M-99.9%	$622.9B
Inventory	$1.4B+0.2%	$1.4B+1.6%	$1.4B-0.1%	$1.4B+3.3%	$1.3B+1.6%	$1.3B+9.3%	$1.2B-99.9%	$1.2T
Accounts Receivable	$3.5B-2.7%	$3.6B+4.4%	$3.5B-3.7%	$3.6B+9.6%	$3.3B-0.1%	$3.3B+0.8%	$3.3B-99.9%	$3.2T
Goodwill	$13.7B+1.3%	$13.5B+0.5%	$13.4B+2.1%	$13.2B+0.9%	$13.0B0.0%	$13.0B-0.3%	$13.1B-99.9%	$13.0T
Total Liabilities	$14.2B+0.3%	$14.2B-2.1%	$14.5B+2.3%	$14.2B+2.4%	$13.8B-2.6%	$14.2B-1.1%	$14.4B-99.9%	$14.1T
Current Liabilities	$5.0B-4.1%	$5.3B+6.8%	$4.9B+10.6%	$4.4B+7.2%	$4.1B+5.5%	$3.9B+8.8%	$3.6B-99.9%	$3.5T
Long-Term Debt	$7.2B+0.4%	$7.2B-6.9%	$7.7B-1.8%	$7.8B-0.1%	$7.9B-6.0%	$8.4B-5.1%	$8.8B-99.9%	$8.6T
Total Equity	$10.8B+2.1%	$10.6B+4.0%	$10.2B-0.1%	$10.2B+3.1%	$9.9B+2.7%	$9.6B+0.6%	$9.6B-99.9%	$9.6T
Retained Earnings	$8.8B+4.6%	$8.4B+4.1%	$8.1B+0.2%	$8.1B+2.9%	$7.9B+4.2%	$7.6B+3.6%	$7.3B-99.9%	$7.3T

FMCQF Cash Flow Statement

Metric	FY16	FY14	FY13	FY11	FY10	FY09
Operating Cash Flow	$2.1B+15.0%	$1.9B-8.5%	$2.0B+40.7%	$1.4B+5.7%	$1.4B+2.2%	$1.3B
Capital Expenditures	$1.0B+10.6%	$931.6M+24.6%	$747.9M+25.1%	$597.9M+14.2%	$523.6M-8.7%	$573.6M
Free Cash Flow	$1.1B+19.4%	$929.8M-27.7%	$1.3B+51.6%	$848.6M+0.5%	$844.5M+10.4%	$765.0M
Investing Cash Flow	-$1.4B+48.7%	-$2.7B-123.2%	-$1.2B+48.6%	-$2.3B-108.5%	-$1.1B-61.2%	-$698.0M
Financing Cash Flow	-$584.8M-172.6%	$805.0M+199.6%	-$808.0M-201.9%	$793.2M+5489.4%	-$14.7M+97.4%	-$558.1M
Dividends Paid	-$277.2M+12.8%	-$317.9M-7.4%	-$296.1M-205.5%	$280.6M+21.0%	$232.0M0.0%	$231.9M
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'16	Q3'16	Q2'16	Q1'16	Q4'15	Q3'15	Q2'15	Q1'15
Operating Cash Flow	$843.6M+92.2%	$438.9M-35.2%	$677.6M+276.9%	$179.8M-67.2%	$548.3M-5.3%	$579.3M	$0-100.0%	$832.5B
Capital Expenditures	$282.4M+16.9%	$241.5M-68.1%	$756.3M+402.3%	-$250.2M-181.9%	$305.6M+33.1%	$229.6M-72.5%	$835.5M+100.2%	-$417.8B
Free Cash Flow	$561.2M+184.4%	$197.3M+351.0%	-$78.6M-11.7%	-$70.4M-129.0%	$242.7M-30.6%	$349.7M+141.9%	-$835.5M-100.2%	$414.7B
Investing Cash Flow	-$451.4M-65.6%	-$272.6M+14.4%	-$318.2M+5.6%	-$337.1M-39.7%	-$241.3M+14.4%	-$281.8M	$0+100.0%	-$477.6B
Financing Cash Flow	-$266.9M-0.2%	-$266.5M-60.3%	-$166.3M-244.7%	$114.9M+130.8%	-$373.3M-55.2%	-$240.5M	$0+100.0%	-$393.8B
Dividends Paid	-$554.4M-200.0%	$554.4M+300.0%	-$277.2M	$0+100.0%	-$526.5M-200.0%	$526.5M+100.0%	$263.2M+100.1%	-$263.2B
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

FMCQF Financial Ratios

Metric	FY16	FY14	FY13	FY11	FY10	FY09
Gross Margin	32.3%+138.1pp	-105.8%-7.2pp	-98.6%-131.6pp	33.0%+0.7pp	32.4%-1.7pp	34.1%
Operating Margin	14.7%-28.1pp	42.8%-2.6pp	45.4%+28.9pp	16.5%+0.3pp	16.2%+0.6pp	15.6%
Net Margin	6.9%-12.9pp	19.9%-2.5pp	22.3%+13.8pp	8.5%+0.3pp	8.3%+0.3pp	7.9%
Return on Equity	11.5%+0.4pp	11.1%-0.9pp	12.0%-1.5pp	13.6%+0.3pp	13.3%-0.1pp	13.4%
Return on Assets	4.6%+0.5pp	4.1%-0.7pp	4.8%-0.7pp	5.5%-0.2pp	5.7%+0.1pp	5.6%
Current Ratio	1.45-0.5	1.93+0.2	1.77+0.4	1.34-0.0	1.36-0.5	1.81
Debt-to-Equity	0.67-0.3	0.95+0.1	0.84+0.1	0.70+0.1	0.58-0.1	0.66
FCF Margin	6.2%-11.5pp	17.7%-8.2pp	25.9%+19.1pp	6.8%-0.4pp	7.1%+0.3pp	6.8%

Metric	Q4'16	Q3'16	Q2'16	Q1'16	Q4'15	Q3'15	Q2'15	Q1'15
Gross Margin	34.0%+2.0pp	32.0%+0.4pp	31.6%+0.3pp	31.3%-34.0pp	65.3%+32.7pp	32.7%+1.8pp	30.9%+73038.0pp	-73007.1%
Operating Margin	16.8%+2.2pp	14.6%+0.1pp	14.5%+1.6pp	12.8%+4.9pp	8.0%-6.5pp	14.5%+1.5pp	13.0%-13271.1pp	13284.2%
Net Margin	8.3%+1.0pp	7.2%+0.6pp	6.7%+1.2pp	5.4%+1.6pp	3.8%-2.4pp	6.2%+0.5pp	5.7%-5513.0pp	5518.8%
Return on Equity	3.6%+0.4pp	3.1%+0.3pp	2.9%+0.6pp	2.2%-1.0pp	3.2%+0.5pp	2.7%+0.2pp	2.5%+0.3pp	2.2%
Return on Assets	1.4%+0.2pp	1.3%+0.1pp	1.1%+0.2pp	0.9%-0.4pp	1.3%+0.2pp	1.0%+0.1pp	0.9%+0.1pp	0.8%
Current Ratio	1.45+0.1	1.37-0.1	1.48-0.1	1.61-0.0	1.63-0.1	1.72-0.1	1.850.0	1.86
Debt-to-Equity	0.67-0.0	0.68-0.1	0.76-0.0	0.77-0.0	0.79-0.1	0.87-0.1	0.92+0.0	0.90
FCF Margin	12.0%+7.7pp	4.3%+6.1pp	-1.8%-0.1pp	-1.7%-4.6pp	2.9%-5.3pp	8.3%+28.2pp	-19.9%-10941.7pp	10921.8%

Frequently Asked Questions

What is Fresenius Med Cr's annual revenue?

Fresenius Med Cr (FMCQF) reported $17.9B in total revenue for fiscal year 2016. This represents a 240.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Fresenius Med Cr's revenue growing?

Fresenius Med Cr (FMCQF) revenue grew by 240.2% year-over-year, from $5.3B to $17.9B in fiscal year 2016.

Is Fresenius Med Cr profitable?

Yes, Fresenius Med Cr (FMCQF) reported a net income of $1.2B in fiscal year 2016, with a net profit margin of 6.9%.

What is Fresenius Med Cr's EBITDA?

Fresenius Med Cr (FMCQF) had EBITDA of $3.4B in fiscal year 2016, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Fresenius Med Cr have?

As of fiscal year 2016, Fresenius Med Cr (FMCQF) had $747.2M in cash and equivalents against $7.2B in long-term debt.

What is Fresenius Med Cr's gross margin?

Fresenius Med Cr (FMCQF) had a gross margin of 32.3% in fiscal year 2016, indicating the percentage of revenue retained after direct costs of goods sold.

What is Fresenius Med Cr's operating margin?

Fresenius Med Cr (FMCQF) had an operating margin of 14.7% in fiscal year 2016, reflecting the profitability of core business operations before interest and taxes.

What is Fresenius Med Cr's net profit margin?

Fresenius Med Cr (FMCQF) had a net profit margin of 6.9% in fiscal year 2016, representing the share of revenue converted into profit after all expenses.

Does Fresenius Med Cr pay dividends?

Yes, Fresenius Med Cr (FMCQF) paid $0.80 per share in dividends during fiscal year 2016.

What is Fresenius Med Cr's return on equity (ROE)?

Fresenius Med Cr (FMCQF) has a return on equity of 11.5% for fiscal year 2016, measuring how efficiently the company generates profit from shareholder equity.

What is Fresenius Med Cr's free cash flow?

Fresenius Med Cr (FMCQF) generated $1.1B in free cash flow during fiscal year 2016. This represents a 19.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Fresenius Med Cr's operating cash flow?

Fresenius Med Cr (FMCQF) generated $2.1B in operating cash flow during fiscal year 2016, representing cash generated from core business activities.

What are Fresenius Med Cr's total assets?

Fresenius Med Cr (FMCQF) had $26.9B in total assets as of fiscal year 2016, including both current and long-term assets.

What are Fresenius Med Cr's capital expenditures?

Fresenius Med Cr (FMCQF) invested $1.0B in capital expenditures during fiscal year 2016, funding long-term assets and infrastructure.

How much does Fresenius Med Cr spend on research and development?

Fresenius Med Cr (FMCQF) invested $162.4M in research and development during fiscal year 2016.

How many shares does Fresenius Med Cr have outstanding?

Fresenius Med Cr (FMCQF) had 306M shares outstanding as of fiscal year 2016.

What is Fresenius Med Cr's current ratio?

Fresenius Med Cr (FMCQF) had a current ratio of 1.45 as of fiscal year 2016, which is considered adequate.

What is Fresenius Med Cr's debt-to-equity ratio?

Fresenius Med Cr (FMCQF) had a debt-to-equity ratio of 0.67 as of fiscal year 2016, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Fresenius Med Cr's return on assets (ROA)?

Fresenius Med Cr (FMCQF) had a return on assets of 4.6% for fiscal year 2016, measuring how efficiently the company uses its assets to generate profit.

What is Fresenius Med Cr's Altman Z-Score?

Fresenius Med Cr (FMCQF) has an Altman Z-Score of 2.05, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Fresenius Med Cr's Piotroski F-Score?

Fresenius Med Cr (FMCQF) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Fresenius Med Cr's earnings high quality?

Fresenius Med Cr (FMCQF) has an earnings quality ratio of 1.72x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Fresenius Med Cr cover its interest payments?

Fresenius Med Cr (FMCQF) has an interest coverage ratio of 5.8x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.